European Notebook: Price Freezes, European Elections To Feature In 2014
Executive Summary
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.
You may also be interested in...
Thousands Of Jobs May Go At Novartis But Worker Headcount To Stay Flat
Novartis plans to support new product launches and other activities around the world by re-allocating up to 4,000 positions, in order to make productivity gains.
Deals Of The Week: New Remedies Sought From Nature And Old Technologies
Sanofi links with researchers at Germany’s Fraunhofer Gesellschaft in the search for new antibiotics while a European joint venture called Hit Discovery Constance GmbH is set up to conduct high-throughput screening for biotech and academic partners. Also, Moderna Therapeutics bags another major partner, GSK exits its DMD deal with Prosensa, and more.
German Ruling Will Prevent Original Products Being Split For Distribution
A German court ruling should protect high-cost original product drugs from being split by re-packagers and sold in smaller batches for profit.